


Rondzending complement


Kyra A. Gelderman, medisch immunoloog
Immunochemie, Sanquin Diagnostiek

Wanneer complement diagnostiek?



- 1) Aangeboren en verkregen complement deficienties
- 2) Afwijkingen met complement activatie


3 routes van activatie






Sanquin

IgG $\gamma\gamma$



Suikers, IgA




Niet beschermd
oppervlak



C4

C2



C5

C6

C7

C8

C9

C9

C9

D

B


P






Sanquin

Complement inhibitie




Waar is complement voor?

1. Doden inringers (bacterien)
2. Amplificeren cellulaire respons
3. Opruimen IgG gecoate partikels
4. Verbeteren B cel (antilichaam) respons
5. Opruimen dode cellen en immuuncomplexen





1) Directe lysis target cel (C5b-9)

1) Doden indringers: geen directe lysis (terminale route deficientie)



Infecties met
gekapselde bacterien
(*N. meningitidis*)




Functie:
CH50/AP50


Concentratie:
C5
C6
C7
C8
C9

AP heeft een steile curve



Een klein verschil in serum conc,
geeft een groot verschil in lysis/C5b-9 depositie



Elisa 1 punt vs titratie/AP50



AP



CP

5) Opruimen Immuuncomplexen en dode cellen

Immuno complex ziekte (SLE) Systemische lupus erythematosis



Figure 11-3 The Immune System, 2/e (© Garland Science 2005)

Concentratie

C1q
C2
C3
C4

Antistoffen

Anti-C1q (monster B)


Rondzending

6 samples A t/m F

2 tot 19 deelnemers per bepaling
goed vergelijkbare resultaten

bepaling		Methodes
C1q	Conc.	Nefelometrie (9)
C3	Conc.	Nefelometrie (11) Turbidimetrie (4)
C4	Conc.	Nefelometrie (14) Turbidimetrie (5)
MBL	Conc.	ELISA (2)
CP	Activiteit	ELISA (14) Hemol assay (2)
AP	Activiteit	ELISA (15) Hemol assay (1)
MBL-P	Activiteit	ELISA (9) ELISA in-house (1)

MBL deficiencies



5–10% van de Kaukasiers (meest voorkomende imm.def.)


3 bekende puntmutaties

MBL →

- instabiel
- bind slecht aan ligand
- slechte LP activatie

MBL functie
(*LP activatie*)

MBL concentratie




~ AIZ / infectie (in combi met andere defecten?)

Promoter polymorphisms: lagere levels van functioneel MBL

Angioedema


(C1 esteraseremmer deficiëntie)




Peroxisomal nocturnal hemoglobinuria

(GPI anker defect: geen CD55 en CD59)


a




b



c



Factor H mutaties en ziekte



Maculaire
degeneratie




complement
regulation

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

attachment
to surfaces

aHUS

mutations in Factor H
especially in SCR-19+20



Doorloper

Bepaling	Gem. resultaat 2012.1 A	Gem. resultaat 2013.1 F	Gem resultaat 2014.A	Gem resultaat 2015.A	Gem resultaat 2016.A
CP (%)	50	48	52	63	56
AP (%)	3.7 (Eurod), 32 (anders)	3.8 (Eurod), 51 (anders)	1.3 (Eurod) 48 (anders)	6.5 (Eurod) 58 (anders)	4.5 (Eurod) 39 (anders)
MBL-P	25	22	21	29	21
C1q (mg/ml)	197	196	180	154	178
C3 (g/l)	1,36	1,30	1,35	1,19	1,32
C4 (g/l)	0,261	0,261	0,264	0,243	0,243
MBL (mg/ml)	1.2	1.95	1.13	1.1	1.1

Conclusie

- Complement is belangrijk
- Het bepalen van complement doen we goed
- Aandachtspunt: interpretatie activiteits assays
- C3 komende rondzending in g/L (2 decimalen)
- C4 komende rondzending in g/L (3 decimalen)